News

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Updated NCCN guidelines now recommend CSF-based genomic profiling for biopsy-infeasible high-grade gliomas and glioblastomas, expanding liquid biopsy use in CNS cancer.

During a live event, Prerna Mewawalla, MD, and participants discussed selecting therapy for patients with early relapsed/refractory multiple myeloma who are not candidates for CAR T-cell therapy.

Ofirnoflast is a first-in-class oral allosteric modulator of NEK7 that previously received FDA orphan drug designation.

At the European Hematology Association Congress, researchers presented on novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

A phase 3 trial of givastomig is expected to begin as early as the fourth quarter of 2026.

A retrospective analysis shows strong outcomes with CAR T-cell therapy in real-world patients with multiple myeloma, Doris K. Hansen, MD, explains.

During a live event, Brittany Siontis, MD, discussed treatment strategies for a patient with a progressive abdominal desmoid tumor.

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

Topline data show no overall survival advantage for lurbinectedin monotherapy or combination therapy over investigators' choice in second-line metastatic small cell lung cancer; drug's first-line maintenance approval remains intact.

The FDA concurrently cleared the VENTANA PTEN (SP218) RxDx assay as a companion diagnostic to identify eligible patients.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

The adjuvant approval of the belzutifan combination is supported by the LITESPARK-022 trial.

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with brain metastases at a single academic center.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

The supplemental biologics license application is supported by the phase 3 ATOMIC trial.

Alembic receives tentative FDA approval for generic larotrectinib capsules, a TRK inhibitor for NTRK fusion–positive solid tumors, with potential 180-day exclusivity.

FDA granted RMAT designation to lasme-cel, a CD22-targeting allogeneic CAR-T, for R/R B-ALL, the first such therapy in a pivotal trial for this indication.

The new designation, which adds to an existing orphan drug designation for the same indication, allows for a priority review voucher and other development incentives.

During a live event, Sikander Ailawadhi, MD, and participants discussed sequencing and bridging therapy selection for patients with early relapsed multiple myeloma who are candidates for CAR T-cell therapy.

Off-the-shelf CD19 CAR T azer-cel earns FDA Fast Track after early trials show striking responses in refractory CLL/SLL and marginal zone lymphoma.

Merck and Gilead discontinue KEYNOTE-D46/EVOKE-03 after combination fails to demonstrate statistically significant progression-free survival benefit over pembrolizumab monotherapy

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

Experts debate first-line poor-risk metastatic ccRCC: ICI‑TKI for rapid control vs dual ICI for durable benefit, guided by updated NCCN 2026.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.